Federal Telehealth Policy Updates for MAT in 2026

The landscape of federal telehealth policy for medication-assisted treatment has undergone dramatic transformation since the COVID-19 emergency ended. What started as temporary flexibilities has evolved into a complex patchwork of permanent rules, pending legislation, and state-level variations that directly impact how millions of Americans access addiction treatment.

For patients considering or currently receiving online Suboxone treatment, understanding these policy changes isn't just academic — it determines whether you can continue your care, what your insurance will cover, and how easy it is to find a provider. The good news? Most of the essential telehealth flexibilities that made treatment more accessible during the pandemic have been preserved or permanently expanded.

In this guide, we'll break down exactly where federal telehealth policy stands in 2026, what's changed from the COVID-era rules, and what these updates mean for your treatment access.

What Changed When the COVID Emergency Ended

The Public Health Emergency (PHE) declaration ended in May 2023, but that wasn't the moment telehealth access collapsed. Instead, Congress and federal agencies worked to transition critical flexibilities into permanent policy.

Key COVID-era rules that expired:

• Automatic blanket waivers for prescribing controlled substances via telehealth
• Universal Medicare telehealth coverage regardless of location
• Simplified state licensing reciprocity for emergency care

What was made permanent or extended:

• DEA's Special Registration pathway for telehealth prescribing of controlled substances (finalized December 2023)
• Medicare telehealth coverage for behavioral health services, including MAT counseling (extended through 2025, then made permanent in early 2026)
• Expansion of originating sites for Medicare telehealth beyond just healthcare facilities

The transition wasn't seamless. Between mid-2023 and early 2024, there was significant uncertainty as providers waited for the DEA to finalize telehealth prescribing rules. Many programs adopted a cautious approach, requiring in-person visits for new patients even when not technically mandated.

The DEA's Permanent Telehealth Prescribing Framework

The Drug Enforcement Administration (DEA) finalized its permanent telehealth prescribing rules in December 2023, replacing the temporary COVID waivers. These rules govern how providers can prescribe buprenorphine (the active ingredient in Suboxone) via telemedicine.

Current DEA requirements for telehealth MAT prescribing:

The DEA created a "Special Registration" pathway that allows providers to prescribe Schedule III-V controlled substances (including buprenorphine) via telehealth after conducting an in-person medical evaluation or a real-time audiovisual telemedicine encounter, as long as the provider meets specific requirements.

For buprenorphine specifically, providers can initiate treatment entirely via telehealth if they:

• Hold an active DEA registration
• Are registered with the DEA for telemedicine (a separate but straightforward registration process)
• Conduct a real-time audiovisual evaluation (not audio-only for initial prescriptions)
• Practice in a state that allows telehealth prescribing for controlled substances

What this means for patients:

You can start Suboxone treatment entirely online without an in-person visit, as long as your provider is properly registered and your state allows it. This is a massive win for accessibility compared to pre-pandemic rules that required in-person evaluation before any controlled substance prescription.

The elimination of the X-waiver requirement (which we covered in detail in our post on DEA X-waiver elimination) combined with these telehealth rules means any DEA-registered provider can prescribe buprenorphine via telemedicine. This has dramatically expanded the provider pool.

Get started with online Suboxone treatment today and connect with a provider within 24 hours.

Medicare Telehealth Coverage in 2026

Medicare's telehealth policies have been extended and expanded multiple times since 2020. As of 2026, here's what's permanent:

Permanently covered via telehealth for Medicare beneficiaries:

• Mental health services, including substance use disorder counseling
• Medication management visits for MAT
• Follow-up visits for established patients
• Group and individual therapy sessions

Location flexibility:

Prior to COVID, Medicare only covered telehealth if the patient was at a designated healthcare facility. That restriction was lifted during the pandemic and permanently removed for behavioral health services in 2026. You can now receive covered telehealth MAT services from your home.

Audio-only coverage:

One of the most significant 2026 updates was making audio-only telehealth permanent for mental health and substance use disorder services. This matters enormously for patients without reliable internet or video-capable devices. While DEA rules require video for initial buprenorphine prescriptions, ongoing counseling and med management can happen by phone for Medicare patients.

What about the Medicare telehealth coverage cliff?

There was concern that broad Medicare telehealth coverage would expire at the end of 2024. Congress acted in late 2024 to extend coverage through 2025, then passed the Telehealth Modernization Act in early 2026, which made most behavioral health telehealth coverage permanent. Geographic restrictions and originating site requirements were permanently eliminated for SUD treatment.

If you're a Medicare beneficiary, your telehealth MAT coverage is now secure and won't face another "coverage cliff" for behavioral health services.

Medicaid Telehealth Policy: State Variations Remain

Unlike Medicare, Medicaid is administered state-by-state, which means telehealth coverage varies significantly depending on where you live. However, federal guidance issued in 2024-2025 encouraged states to maintain COVID-era telehealth flexibilities, and most have complied.

Federal Medicaid guidance on telehealth MAT (2026):

The Centers for Medicare & Medicaid Services (CMS) issued updated guidance stating that federal matching funds (FMAP) will support state Medicaid programs that cover:

• Audio-only telehealth for behavioral health services
• Home-based telehealth for SUD treatment
• Asynchronous store-and-forward telehealth for care coordination

State-level Medicaid telehealth coverage:

As of 2026, all three states where Grata Health operates have maintained robust telehealth coverage:

• Virginia: Virginia Medicaid covers telehealth MAT with audio-only options and no geographic restrictions
• Ohio: Ohio Medicaid expanded permanent coverage in 2025, including audio-only for follow-ups
• Pennsylvania: Pennsylvania Medicaid maintained all COVID-era flexibilities and added coverage for remote patient monitoring

Check our detailed state guides for specifics on Virginia, Ohio, and Pennsylvania Medicaid coverage policies.

Private Insurance Telehealth Coverage Mandates

Private insurance coverage of telehealth services is governed by a mix of federal law, state mandates, and individual plan policies. The big question: Are insurers required to cover telehealth MAT the same way they cover in-person treatment?

Federal parity laws:

The Mental Health Parity and Addiction Equity Act (MHPAEA) requires that insurers cover mental health and substance use disorder treatment at the same level as medical/surgical care. In 2024, federal regulators clarified that this parity requirement extends to telehealth modalities — insurers can't impose restrictions on telehealth SUD treatment that they don't impose on in-person care.

What this means practically:

If your plan covers in-person buprenorphine treatment, it must also cover telehealth buprenorphine treatment. Insurers cannot:

• Require prior authorization for telehealth visits if they don't require it for in-person
• Impose higher copays for telehealth MAT services
• Limit the number of telehealth visits more strictly than in-person visits

Major insurers' 2026 policies:

Most major commercial insurers have formalized permanent telehealth coverage:

• Aetna covers telehealth MAT with no prior authorization for established patients
• Blue Cross Blue Shield plans (including Anthem and Highmark) cover video and audio-only telehealth
• Cigna and Humana have similar parity-compliant policies

ACA Marketplace plans are also required to cover telehealth SUD services. Our guide to ACA Marketplace plans and Suboxone coverage has more details.

Pending Federal Legislation (2026 Session)

Several bills currently moving through Congress could further expand or restrict telehealth access for MAT. Here's what's in play:

The TREAT Act (Telehealth Response for E-prescribing Addiction Therapy Act):

This bipartisan bill would permanently codify the DEA's telehealth prescribing framework into federal law, removing the risk that a future administration could reverse the regulations. It also includes funding for rural telehealth infrastructure and provider training.

Status: Passed the House in March 2026, currently in Senate committee. Broad bipartisan support suggests likely passage by late 2026.

The Telehealth Extension and Evaluation Act:

This bill would extend several temporary Medicare telehealth waivers and fund a comprehensive study of telehealth outcomes for chronic conditions, including addiction. While most behavioral health provisions are now permanent, this would extend coverage for other conditions and add funding for telehealth evaluation research.

Status: In committee, expected to be included in a year-end spending package.

State Telehealth Uniformity Act:

This bill aims to create interstate licensure compacts specifically for telehealth providers, making it easier for addiction medicine specialists to treat patients across state lines. Currently, providers must be licensed in each state where their patients are located during appointments.

Status: Early stages, introduced in the Senate but not yet scheduled for markup. More controversial due to state sovereignty concerns.

None of these bills would restrict current telehealth access — they're all expansion or maintenance measures. The political consensus is that telehealth MAT has proven effective and accessible, and there's little appetite to roll back access.

State Licensing and Interstate Practice

One area where federal policy still lags is interstate medical practice. The DEA allows telemedicine prescribing across state lines, but state medical boards require providers to hold licenses in the state where the patient is physically located during the appointment.

Current interstate licensure landscape:

Some states participate in the Interstate Medical Licensure Compact (IMLC), which streamlines the process for obtaining multiple state licenses. However, the compact doesn't cover all states, and it still requires separate licenses — it just makes getting them easier.

What this means for patients:

If you're receiving telehealth treatment while traveling, you need to ensure your provider is licensed in the state where you're currently located. Most telehealth MAT programs, including Grata Health, restrict services to states where they maintain provider licenses.

There's growing momentum for either expanding the IMLC or creating a federal framework for telehealth-specific licensure. The State Telehealth Uniformity Act (mentioned above) represents one approach to solving this problem.

Audio-Only vs. Video: What's Required?

One persistent question: Can you do everything by phone, or do you need video capability?

DEA rules (controlled substance prescribing):

• Initial buprenorphine prescription: Must be via real-time audiovisual (video) telemedicine
• Refills and follow-ups: Can be audio-only once treatment is established

Medicare/Medicaid rules (counseling and non-prescribing services):

• Both video and audio-only are covered for therapy and counseling sessions
• Audio-only is explicitly protected for mental health and SUD services

Private insurance:

Most private insurers follow federal guidance and cover both video and audio-only for behavioral health services, but verify with your specific plan.

Practical implications:

You need video access for your first telehealth appointment if you're starting buprenorphine. After that, many programs offer phone-based check-ins and counseling. This is especially valuable for patients with unreliable internet or who live in rural areas without broadband.

Privacy and Security Requirements

Federal telehealth policy includes strict requirements to protect patient privacy, especially for substance use disorder treatment.

HIPAA compliance:

All telehealth platforms used for MAT must be HIPAA-compliant. Consumer video apps like FaceTime or Zoom (consumer version) don't meet HIPAA standards. Providers must use secure, healthcare-specific platforms.

Our detailed guide to telehealth privacy and HIPAA in addiction treatment covers what to expect.

42 CFR Part 2 (additional SUD privacy protections):

Federal regulations provide extra privacy protection for substance use disorder treatment records, beyond standard HIPAA rules. These protections apply equally to telehealth and in-person care. Learn more in our post on treatment confidentiality under 42 CFR Part 2.

Key patient protections:

• Your SUD treatment records can't be disclosed without your written consent, even to other healthcare providers
• Your employer can't access records of MAT treatment covered by employer-sponsored insurance (with specific protections outlined in our guide to employer insurance privacy in MAT)
• Telehealth platforms must use end-to-end encryption and secure data storage

What Providers Need to Know (If You're a Clinician)

If you're a healthcare provider reading this, here's what you need to have in place to prescribe buprenorphine via telehealth in 2026:

Registration requirements:

1. Active DEA registration
2. DEA Special Registration for telemedicine (apply via DEA.gov)
3. State medical license in the state where each patient is located during appointments
4. State-specific controlled substance registration if required

Technology requirements:

1. HIPAA-compliant video platform with end-to-end encryption
2. Electronic prescribing system that meets EPCS (Electronic Prescribing for Controlled Substances) standards
3. Backup communication methods for technical failures

Initial evaluation requirements:

1. Real-time audiovisual encounter for first buprenorphine prescription
2. Standard medical history and physical assessment adapted for telehealth
3. Documentation meeting DEA requirements (same as in-person)

Follow-up care:

1. Can be video or audio-only after initial prescription
2. Must meet standard-of-care requirements for ongoing monitoring
3. State-specific follow-up requirements may apply

Detailed provider guidance is available in our post on telehealth prescribing regulations in 2026 and through DEA and SAMHSA technical assistance resources.

Comparing 2026 Policy to Pre-Pandemic and COVID-Era Rules

It's helpful to see how far we've come:

Pre-pandemic (2019):

• In-person visit required before any buprenorphine prescription
• DEA X-waiver required to prescribe buprenorphine (limited to specially trained providers)
• Medicare telehealth only covered if patient was at a healthcare facility
• No audio-only coverage for any Medicare services
• Most private insurers didn't cover telehealth or imposed significant restrictions

COVID emergency (2020-2023):

• DEA waived in-person requirement entirely
• Medicare telehealth available from patient's home
• Audio-only temporarily covered
• Most states expanded Medicaid telehealth coverage
• Private insurers adopted broader telehealth policies

Current policy (2026):

• Video visit required for initial buprenorph